专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6030812A Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors 失效
标题翻译：包含多重突变白细胞介素-3（IL-3）多肽和第二生长因子的融合蛋白
公开(公告)号：US6030812A
公开(公告)日：2000-02-29
申请号：US468609
申请日：1995-06-06
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan M. Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan M. Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： C12N15/09 , A47B47/02 , A61K38/00 , A61K38/20 , A61K38/22 , A61K38/27 , A61P7/00 , C07H21/04 , C07K20060101 , C07K14/52 , C07K14/53 , C07K14/54 , C07K19/00 , C12N1/21 , C12N15/24 , C12N15/26 , C12N15/27 , C12N15/62 , C12N15/63 , C12P21/02 , C12R1/19
CPC分类号： C07K14/5403 , A61K38/00 , C07K2319/00 , C07K2319/02
摘要： The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
摘要翻译：本发明涉及与其他集落刺激因子（CSF），细胞因子，淋巴因子，白介素，造血生长因子或IL-3变体融合的人白细胞介素-3（hIL-3）变体或突变蛋白（突变蛋白）。

2. 发明授权

US6022535A Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors 失效
标题翻译：用包含多重突变白细胞介素-3（IL-3）多肽和第二生长因子的融合蛋白治疗造血障碍
公开(公告)号：US6022535A
公开(公告)日：2000-02-08
申请号：US469318
申请日：1995-06-06
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helen Caparon , Alan M. Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helen Caparon , Alan M. Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： C12N15/09 , A47B47/02 , A61K38/00 , A61K38/20 , A61K38/22 , A61K38/27 , A61P7/00 , C07H21/04 , C07K20060101 , C07K14/52 , C07K14/53 , C07K14/54 , C07K19/00 , C12N1/21 , C12N15/24 , C12N15/26 , C12N15/27 , C12N15/62 , C12N15/63 , C12P21/02 , C12R1/19
CPC分类号： C07K14/5403 , A61K38/00 , C07K2319/00 , C07K2319/02
摘要： The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
摘要翻译：本发明涉及与其他集落刺激因子（CSF），细胞因子，淋巴因子，白介素，造血生长因子或IL-3变体融合的人白细胞介素-3（hIL-3）变体或突变蛋白（突变蛋白）。

3. 发明授权

US5451604A Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives 失效
标题翻译：卤代苯乙腈烷基氨基烷基苯基化合物作为免疫抑制剂
公开(公告)号：US5451604A
公开(公告)日：1995-09-19
申请号：US97809
申请日：1993-07-26
申请人： Richard A. Mueller , Thomas E. Barta , John P. McKearn , Susan A. Gregory , Richard A. Partis , Francis J. Koszyk
发明人： Richard A. Mueller , Thomas E. Barta , John P. McKearn , Susan A. Gregory , Richard A. Partis , Francis J. Koszyk
IPC分类号： C07C255/42 , A61K31/275 , C07C247/06 , C07C255/35
CPC分类号： C07C255/42 , C07C2101/10
摘要： A class of halogenated phenylacetonitrile alkylaminoalkylphenyl compounds having immunosuppressive properties is described. Compounds of this class would be useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune or inflammatory diseases. Compounds of particular interest are of the formula ##STR1## wherein m is a number selected from three to five, inclusive; wherein n one or two; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl and phenethyl; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl and phenethyl; wherein each of R.sup.3 through R.sup.7 is selected from hydrido, fluoro, chloro, bromo, azide, trifluoromethyl, difluorochloromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,2,3-tetrafluoropropyl; with the proviso that at least one of R.sup.3 through R.sup.7 is selected from fluoro and trifluoromethyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
摘要翻译：描述了一类具有免疫抑制特性的卤代苯基乙腈烷基氨基烷基苯基化合物。该类化合物可用于减少移植器官的受体排斥和治疗自身免疫性或炎性疾病。特别感兴趣的化合物具有下式：其中m是选自三至五的数字，包括端值; 其中n个或两个; 其中R1选自甲基，乙基，正丙基，异丙基，正丁基，仲丁基，叔丁基，异丁基，正戊基，异戊基，环丙基，环丁基，环戊基，环己基，环丙基甲基，环丁基甲基，环戊基甲基，环己基甲基，苄基和苯乙基; 其中R2选自甲基，乙基，正丙基，异丙基，正丁基，仲丁基，叔丁基，异丁基，正戊基，异戊基，环丙基，环丁基，环戊基，环己基，环丙基甲基，环丁基甲基，环戊基甲基，环己基甲基，苄基和苯乙基; 其中R3至R7各自选自氢，氟，氯，溴，叠氮化物，三氟甲基，二氟氯甲基，1,1-二氟乙基，2,2,2-三氟乙基，全氟乙基和2,2,2,3-四氟丙基; 条件是R3至R7中的至少一个选自氟和三氟甲基; 或其互变异构体或其药学上可接受的盐。

4. 发明授权

US5162569A Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives 失效
标题翻译：作为免疫抑制剂的苯乙烯胺基甲基亚氨基亚氨基取代的芳基化合物
公开(公告)号：US5162569A
公开(公告)日：1992-11-10
申请号：US623596
申请日：1990-12-12
申请人： Chi-Dean Liang , John P. McKearn , John M. Farah, Jr. , Richard A. Mueller
发明人： Chi-Dean Liang , John P. McKearn , John M. Farah, Jr. , Richard A. Mueller
IPC分类号： A61K31/275 , A61P11/00 , A61P29/00 , A61P31/04 , A61P37/06 , A61P37/08 , C07C255/43 , C07C275/14 , C07C275/40 , C07C327/30
CPC分类号： C07C255/43
摘要： A class of substituted phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds having immunosuppressive properties is described. Compounds of this class would be useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune or inflammatory diseases. Compounds of particular interest are of the formula ##STR1## wherein m is one or two; wherein n is a number selected from one to five, inclusive; wherein R.sup.1 is selected from hydrido, alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, alkenyl and alkynyl; wherein R.sup.6 is selected from loweralkyl; wherein each of R.sup.8, R.sup.9, R.sup.10 and R.sup.12 through R.sup.16 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, alkoxy, alkenyl, alkynyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylalkenyl, alkylaminocarbonyl and alkoxyalkyl; with the proviso that at least one of R.sup.12 and R.sup.16 must be selected from hydroxy, alkyl, hydroxyalkyl, alkoxy, alkenyl, alkynyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylalkenyl, alkylaminocarbonyl and alkoxyalkyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

5. 发明授权

US06440407B1 Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides 失效
标题翻译：使用白细胞介素-3（IL-3）多重突变多肽的造血细胞离体扩增的方法
公开(公告)号：US06440407B1
公开(公告)日：2002-08-27
申请号：US08764114
申请日：1996-12-09
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： C12N508
CPC分类号： C07K14/5403 , A61K38/00 , C07K2319/00 , C07K2319/02 , Y10S930/141
摘要： The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
摘要翻译：本发明涉及通过在包含多个氨基酸取代的人白细胞介素-3（hIL-3）的变体的生长培养基中培养造血细胞而造血细胞离体扩增的方法，其可以具有天然hIL的部分 -3分子删除。本发明还涉及用于基因治疗的造血细胞的离体扩增。此外，本发明涉及扩大的造血细胞用于治疗造血障碍的患者的用途。

6. 发明授权

US06436387B1 Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins 失效
标题翻译：使用多变量IL-3造血嵌合体蛋白质造血细胞离体扩增的方法
公开(公告)号：US06436387B1
公开(公告)日：2002-08-20
申请号：US08762227
申请日：1996-12-09
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： A61K4500
CPC分类号： C07K14/5403 , A61K38/00 , C07K2319/00 , C07K2319/02
摘要： The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a chimera protein which comprises a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted and a hematopoietic growth factor. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
摘要翻译：本发明涉及通过在包含嵌合体蛋白质的生长培养基中培养造血细胞的造血细胞的离体扩增方法，所述嵌合体蛋白质包含含有多个氨基酸取代的人白细胞介素-3（hIL-3）的变体，天然hIL-3分子缺失的部分和造血生长因子。本发明还涉及用于基因治疗的造血细胞的离体扩增。此外，本发明涉及扩大的造血细胞用于治疗造血障碍的患者的用途。

7. 发明申请

US20080004281A1 METHODS FOR THE MODULATION OF CRP BY THE SELECTIVE MODULATION OF PPAR DELTA 审中-公开
标题翻译：通过PPAR DELTA的选择性调节来调节CRP的方法
公开(公告)号：US20080004281A1
公开(公告)日：2008-01-03
申请号：US11768887
申请日：2007-06-26
申请人： Tadimeti S. Rao , John P. McKearn , Mausumee Guha
发明人： Tadimeti S. Rao , John P. McKearn , Mausumee Guha
IPC分类号： A61K31/495 , A61K31/4985 , A61P19/02
CPC分类号： A61K31/495 , A61K31/4985
摘要： The present invention discloses methods to reduce C-reactive protein (CRP) in patients in need thereof comprising the selective modulation of PPARδ.
摘要翻译：本发明公开了在有需要的患者中减少C-反应蛋白（CRP）的方法，其包括PPARδ的选择性调节。

8. 发明授权

US06858598B1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia 失效
标题翻译：使用基质金属蛋白酶抑制剂和一种或多种抗肿瘤药物作为治疗肿瘤的联合疗法
公开(公告)号：US06858598B1
公开(公告)日：2005-02-22
申请号：US09857995
申请日：1999-12-22
申请人： John P. McKearn , Gary Gordon , James J. Cunningham , Stephen T. Gately , Alane T. Koki , Jaime L. Masferrer
发明人： John P. McKearn , Gary Gordon , James J. Cunningham , Stephen T. Gately , Alane T. Koki , Jaime L. Masferrer
IPC分类号： A61K31/135 , A61K31/415 , A61K31/42 , A61K31/445 , A61K31/505 , A61K31/506 , A61K31/675 , A61K33/24 , A61K41/00 , A61K45/06 , A61K31/33 , C07D211/00 , C07D295/00 , C07D417/00
CPC分类号： A61K33/24 , A61K31/135 , A61K31/415 , A61K31/42 , A61K31/445 , A61K31/505 , A61K31/506 , A61K31/675 , A61K41/00 , A61K41/0038 , A61K45/06 , A61K2300/00
摘要： A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
摘要翻译：公开了一种使用MMP抑制剂和任选的放射治疗的方法，以及一种或多种选自伊立替康和托泊替康的拓扑异构酶类抗肿瘤剂作为治疗肿瘤的组合疗法。

9. 发明授权

US06361976B1 Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production 失效
标题翻译：将白细胞介素-3突变体多肽与CSFS共同给予多谱系造血细胞生产
公开(公告)号：US06361976B1
公开(公告)日：2002-03-26
申请号：US08446871
申请日：1995-06-06
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： C12N2100
CPC分类号： C07K14/5403 , A61K38/00 , A61K38/18 , A61K38/1816 , A61K38/193 , A61K38/20 , A61K38/27 , C07K2319/00 , C07K2319/02 , A61K2300/00
摘要： The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
摘要翻译：本发明涉及与其它集落刺激因子（CSF），细胞因子，淋巴因子，白细胞介素，造血生长因子或IL-3变体功能性共同施用的人白细胞介素-3（hIL-3）变体或突变蛋白（突变蛋白）。

10. 发明授权

US6060047A Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production 失效
标题翻译：共同给予白细胞介素-3突变体多肽与CSF用于多系造血细胞生产
公开(公告)号：US6060047A
公开(公告)日：2000-05-09
申请号：US471045
申请日：1995-06-06
申请人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
发明人： S. Christopher Bauer , Mark Allen Abrams , Sarah Ruth Braford-Goldberg , Maire Helena Caparon , Alan Michael Easton , Barbara Kure Klein , John P. McKearn , Peter O. Olins , Kumnan Paik , John W. Thomas
IPC分类号： A61K38/20 , A61K45/00 , C07K14/54 , C12N15/24 , C12N15/62 , C12P21/04
CPC分类号： A61K45/00 , A61K38/1816 , A61K38/193 , C07K14/5403 , A61K38/00
摘要： The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
摘要翻译：本发明涉及与其他集落刺激因子（CSF），细胞因子，淋巴因子，白介素，造血生长因子或IL-3变体功能性共同施用的人白细胞介素-3（hIL-3）变体或突变蛋白（突变蛋白）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式